Global Alopecia Treatment Market – Market Insights
Alopecia is the condition described for excessive hair damage or hair loss. Alopecia treatment plays a major role in advanced healthcare, as it aids in prevention of hair fall and regrowth of hair. The unhealthy lifestyle, ageing, and hormonal imbalance are some of the factors leading to alopecia condition.
The global alopecia treatment market size was valued at US$ 7,325.0 million in 2017, and is expected to exhibit a CAGR of 4.9% over the forecast period (2018–2026).
Figure 1. Global Alopecia Treatment Market Value (US$ Mn), by Region, 2018
Source: Coherent Market Insights Analysis (2019)
Increasing product approvals, product launches, and robust pipelines are expected to propel the market growth
Rising product launch and robust pipelines are expected to drive the global alopecia treatment market. For instance, in November 2018, Fidia Pharma launched Trinov hair growth lotion for hair growth in Italy. Furthermore, in September 2018, Eli Lilly and Company initiated phase 2 clinical trial to assess the safety and efficacy of Baricitinib drug in treating patients with alopecia areata. The study is estimated to complete in August 2022.
Rising initiatives such as crowdfunding campaigns and increasing collaboration by the market players is expected to bolster the market growth. For instance, in 2018, HairClone, a U.K. based company working on cellular hair restoration therapies, launched its public crowdfunding campaign. The company collaborated with Capital Cell, a crowdfunding company. Similarly, in May 2013, RepliCel Life Sciences Inc. and Shiseido Company, Limited announced collaboration and technology development transfer framework agreement for RepliCel’s RCH-01 hair regeneration technology.
Figure 2. Global Alopecia Treatment Market Share (%), by Disease Type, 2018 and 2026
Source: Coherent Market Insights Analysis (2019)
Increasing prevalence of Alopecia Areata and higher focus on advancing research in the North America are expected to bolster the market growth
North America holds dominant position in the global alopecia treatment market, owing to increasing prevalence of Alopecia Areata and active research activities by market players. For instance, according to the National Alopecia Areata Foundation (NAAF), 2017, alopecia areata affects around 6.8 million people in the U.S. with a lifetime risk of 2.1%. Moreover, the NAAF is focused on broadening research efforts through two committees, including the Basic Research Advisory Council (BRAC), and the Clinical Research Advisory Council (CRAC), in order to advance the Alopecia Areata Treatment Development Program
Increasing acquisition strategies in the region by the market players are major factor expected to propel the market growth. For instance, in August 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., which expanded Aclaris’ inflammation and immunology pipeline with the addition of Confluence’s lead product candidates CDD-450, topical Janus kinase inhibitors, and IL2-inducible T-cell kinase inhibitor programs.
Moreover, collaboration of market players with regulatory authorities as well as other government organizations is further expected to support growth of the North America alopecia treatment market over the forecast period. For instance in April, 2019, Precision Therapeutics Inc., Helomics, and the National Alopecia Areata Foundation (NAAF), entered into an agreement to treat people affected by an autoimmune skin disease called alopecia areata. The agreement was intended to provide a next-generation patient registry to drive research on new treatments for people with this disease.
Major players operating in the global alopecia treatment market include Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., Merck & Co., Inc., Daiichi Sankyo Company, Limited, and Sun Pharmaceutical Industries Ltd.
Alopecia is the common autoimmune disorder, which causes hair loss or sometimes it may lead to baldness. Alopecia is classified into alopecia areata, androgenic alopecia, alopecia totalis, and cicatricial alopecia. Alopecia areata is a common autoimmune disorder that results in unpredictable hair loss. In this case, the body attacks its own anagen hair follicles and suppresses or stops hair growth. Cicatricial alopecia is the condition characterized by hair loss accompanied by the formation of scars.
Increasing product launches by market players is a major factor driving global alopecia treatment market growth. For instance, in March 2016, Galderma Laboratories, L.P. announced the launch of qilib Hair Regrowth + Revitalization System and qilib Hair Health Reinforcement Biotin + Multivitamin Supplement indicated for hair thinning problem and hair loss.
Furthermore, inorganic strategies adopted by key players for enhancing their distribution network and offering best products in the market is expected to drive the market growth. For instance, in May 2018, Cellmid Limited entered into an agreement with Beijing Fukangren Bio-pharm Tech Co Ltd. for distribution of its products across People’s Republic of China.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 31 market data tables and 25 figures on "Alopecia Treatment Market - Global forecast to 2026”.
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.